03-29-06.

Approved for use through 07/31/2006. OMB 0851-050. U.S. Patent and Trademan Citice, U.S. DePARTMENT OF COMM U.S. Patent and Trademan Citice, U.S. DEPARTMENT OF COMM INTERPRETATION OF COMM INTERPRETATION OF COMMITTED INTERPRETA	MAH & B TOOD &	<u>)</u>				PTO/SB/21 (09-	
TRANSMITTAL FORM (to be used for all correspondence after initial filing) Total Number of Pages in This Submission Total Number of Pages in This Submission ENCLOSURES (Check all that apply) Fee Transmittal Form Fee Attached Amendment/Reply After Final After Allowance Communication to Board of Appeals and Interferences Appeal Communication to TO (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Copy of International Search Report X Information Disclosure Statement Copy of Priority Document(s) Document(s) Request for Refund Copy of Priority Document(s) Cartified Copy of Priority Document(s) Cartified Copy of Priority Document(s) Report of Massing Parts Incomplete Application Report to Missing Parts Incomplete Application Report to Missing Parts under SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name DARBY & DARBY P.C. Signature DARBY & DARBY P.C.	Transfeller	Punts Reduction Act of 1995, no	normane are required	U.S. Pa	stant and Trac	d for use through 07/31/2006. OMB 0651-0031	
First Named Inventor First Named Inventor Daniel Rodriguez Greve Art Unit Examiner Name Not Yet Assigned Examiner Name Not Yet Assigned Examiner Name Not Yet Assigned Dos432/100M668-US1 ENCLOSURES (Check all that apply) ENCLOSURES (Check all that apply) Fee Transmittal Form Drawing(s) Fee Attached Licensing-related Papers Appeal Communication to Board of Appeals and Interferences Appeal Communication to To To (Appeal Notice, Brief, Reply Brief) After Final Petition Petition Convert to a Provisional Application Provisional Application Proprietary Information Status Letter Extension of Time Request Extension of Time Request Information Disclosure Statement Cop, Number of CD(s) Document(s) Coruffied Copy of Priority Document(s) Corumnication to To (Appeal Notice, Brief, Reply Brief) Reply to Missing Parts Incomplete Application Reply to Missing Parts under Signature DARBY & DARBY P.C.	CDINGE PICT OPE	THOM THE GOOD OF THE SON, THE	persons are required	Application I	Number		
Art Unit Not Yet Assigned Examiner Name Daniel Rodriguez Greve Art Unit Not Yet Assigned Examiner Name Docket Number Total Number of Pages in This Submission Alterney Docket Number Drawing(s) ENCLOSURES (Check all that apply) ENCLOSURES (Check all that apply) Fee Transmittal Form Drawing(s) Fee Attached Licensing-related Papers Appeal Communication to Tot Appeals and Interferences Amendment/Reply Petition Petition Petition Appeals Communication to Tot (Appeal Notice, Brief, Reply Brief) After Final Petition to Convert to a Provisional Application Proprietary Information Affidavits/declaration(s) Power of Attorney, Revocation Change of Correspondence Address Extension of Time Request Request Request for Refund Proprietary Information Status Letter Information Disclosure Statement CD, Number of CD(s) Copy of International Search Report Copies of 50 References (Document(s) (Document(s) Status Letter) Copy of International Search Report Copies of 50 References (Document(s) Status Letter) Copy of International Search Report Copies of 50 References (Document(s) Status Letter) Copy of International Search Report Copies of 50 References (Document(s) Status Letter) Copy of International Search Report Copies of 50 References (Document(s) Status Letter) Copy of International Search Report Copies of 50 References (Document(s) Status Letter) Copy of International Search Report Copies of 50 References (Document(s) Status Letter) Copy of International Search Report Copies of 50 References (Document(s) Status Letter) Copy of International Search Report Copies of 50 References (Document(s) Status Letter Co	TE	RANSMITT	AL	Filing Date		September 14, 2005	
(to be used for all correspondence after initial filing) Examiner Name Not Yet Assigned Attorney Docket Number 05432/100M668-US1 ENCLOSURES (Check all that apply) Fee Transmittal Form Drawing(s) Fee Attached Licensing-related Papers Appeal Communication to To To Appeals and Interferences Appeal Communication to To To Appeal Sommunication to To Appeal Sommunication to To Appeal Sommunication to To To Appeal Notice, Brief, Reply Brief) After Final Proprietary Information Proprietary Information Status Letter Other Enclosure(s) (please Identify blow): Copy of International Search Report Copies of 50 References (Document Source) Signature Signature Of APPLICANT, ATTORNEY, OR AGENT Firm Name DARBY & DARBY P.C. Signature DARBY & DARBY P.C.		FORM		First Named	Inventor	Daniel Rodriguez Greve	
Examiner Name Not Yet Assigned Total Number of Pages in This Submission Alterney Docket Number ENCLOSURES (Check all that apply) ENCLOSURES (Check all that apply) Fee Transmittal Form Fee Attached Licensing-related Papers Appeal Communication to Board of Appeals and Interferences Armendment/Reply After Final Petition to Convert to a Provisional Application Provisional Application Prover of Atterney, Revocation Change of Corresponderce Address Extension of Time Request Express Abandonment Request Express Abandonment Request Copy of International Search Report Terminal Disclaimer Copy of International Search Report Request for Refund Copy of Priority Document(9) Reply to Missing Parts Report to Missing Parts under Signature Signature Of APPLICANT, ATTORNEY, OR AGENT Firm Name DARBY & DARBY P.C. Signature Provisional Application After Final Provisional Application Appeal Communication to Board of Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Proprietary Information Status Letter Copy of International Search Report Request for Refund Copy of International Search Report Request for Refund Copy of International Search Report Remarks Remarks Remarks Signature DARBY & DARBY P.C. Signature DARBY & DARBY P.C.	fin he use	d for all correspondence after	initial filing)	Art Unit	•	Not Yet Assigned	
ENCLOSURES (Check all that apply) Fee Transmittal Form	(10 20 000	o for all concepting the	mica may	Examiner Na	ame	Not Yet Assigned	
Fee Transmittal Form Drawing(s)	Total Number	of Pages in This Submiss	ion	Attorney Do	cket Number	05432/100M668-US1	
Fee Attached Clicensing-related Papers		EN	CLOSURES	(Check all	that appl	()	
Amendment/Reply After Final Petition to Convert to a Provisional Application After Final After Final Provisional Application Power of Atterney, Revocation Change of Corresponderce Address Extension of Time Request Express Abandonment Request Express Abandonment Request Copy of International Search Report Copy of Priority Document(9) Reply to Missing Parts under Report	Fee Transm	nittal Form	Drawing(s)				
Petition to Convert to a Provisional Application Provisional App	Fee A	Attached	Licensing-rel	ated Papers		Appeal Communication to Board of Appeals and Interferences	
Provisional Application Provisional Appl	Amendmen	t/Reply	Petition				
Extension of Time Request Express Abandonment Request Information Disclosure Statement Cortified Copy of Priority Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Signature DARBY & DARBY P.C. Signature Correspondence Address Incomplete Address Incomplete Address Incomplete Application SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Signature Manuel DARBY & DARBY P.C. Signature Manuel DARBY & DARBY P.C.					Proprietary Information		
Express Abandonment Request Express Abandonment Request Information Disclosure Statement CD, Number of CD(s) Copyer of Tolerandional Search Report Copies of 50 References (Cocument Nos. 1-50) Return Receipt Postcard Remarks Remarks Remarks SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Signature DARBY & DARBY P.C. Signature Multiple Signature Multiple Signature DARBY & DARBY P.C.	Affida	vits/declaration(s)				Status Letter	
Report Copies of 50 References (Document Nos. 1-50) Certified Copy of Priority Landscape Table on CD Return Receipt Postcard	Extension of	of Time Request	Terminal Dis-	claimer .			
Confided Copy of Priority Landscape Table on CD Return Receipt Postcard	Express Ab	andonment Request	Request for	Refund			
Cartified Copy of Priority Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name DARBY & DARBY P.C. Signature Multiple Base Priority Description Return Receipt Postcard Remarks Remarks Remarks SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name DARBY & DARBY P.C.	x Information	Disclosure Statement	CD, Number	of CD(s)			
Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name DARBY & DARBY P.C. Signature Multiple Base Philade Agency Bignature Multiple Base			Landso	ape Table on	CD		
Incomplete Application Signature OF APPLICANT, ATTORNEY, OR AGENT Signature DARBY & DARBY P.C. Signature Multiple Bank Billingtone							
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name DARBY & DARBY P.C. Signature Multiple Bank Billions area.		Remarks					
Firm Name DARBY & DARBY P.C. Signature Multiple Bank Brighed name	Reply to Missing Parts under						
Firm Name DARBY & DARBY P.C. Signature Multiple Bank Brighed name							
Firm Name DARBY & DARBY P.C. Signature Multiple Bank Brighed name							
Signature Multiple Bank		SIGNATI	JRE OF APPLICA	ANT, ATTOR	RNEY, OR	AGENT	
Printed pages	Firm Name	DARBY & DARBY P	.C.				
Printed name	Signature	Millett B	Bark				
Mitchell Bernstein, Ph.D.	Printed name	Mitchell Bernstein, F	h.D.				
Date March 28, 2006 Reg. No. 46,550	Date	March 28, 2006			Reg. No.	46,550	

Express Mail Label No.	Dated:	



Docket No.: 05432/100M668-US1 (PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Daniel Rodriguez Greve et al.

Application No.: 10/549,345

Filed: September 14, 2005 Art Unit: Not Yet Assigned

For: SUBSTITUTED ANILINE DERIVATIVES Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application as required by 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and Trademark Office has waived this requirement for all U.S. patent applications. Applicant submits herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).

Also enclosed is an International Search Report, dated July 20, 2004, which issued during the prosecution of International Application No. PCT/DK2004/000162, which corresponds to the present application.

Documents no. 1, 3, 5, 7, 8, and 11 on the attached PTO/SB/08 are not in English.

Documents 1, 7, and 11 are cited on the aforementioned International Search Report. Documents 5 and 8 include English language abstracts. A separate English language abstract is provided for document 3. Further reference to these documents is found in the specification at page 2, lines 24-25 (document 3); page 5, lines 17-24 (document 5); and page 5, lines 6-8 (document 8). Thus, the required concise explanation of the relevance of documents 1, 3, 5, 7, 8, and 11 is believed to be provided.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee to Deposit Account No. 04-0100.

Dated: March 28, 2006

Respectfully submitted.

Mitchell Bernstein, Ph.D. Registration No.: 46,550

Registration No.: 46,55 DARBY & DARBY P.C.

P.O. Box 5257

New York, New York 10150-5257

(212) 527-7700 (212) 527-7701 (Fax)

Attorneys/Agents For Applicant



PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Palent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/B/PTO Application Number 10/549.345 INFORMATION DISCLOSURE September 14, 2005 Filing Date STATEMENT BY APPLICANT First Named Inventor Daniel Rodriguez Greve Art Unit Not Yet Assigned (Use as many sheets as necessary) Examiner Name Not Yet Assigned Sheet 1 of 3 Attorney Docket Number 05432/100M668-US1

	U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (If known)	Publication Date MM-DD-YYYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			

	FOREIGN PATENT DOCUMENTS							
Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,			
nitials*	No.1	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	™		
/SY/	1	EP 0 386 452 B1	09-12-1990	BASF Aktiengesellschaft				
/SY/	2	EP 0 515 684 A1	12-02-1992	Chugai Seiyaku Kabushiki Kaisha				
/SY/	3	EP 0 554 543 A2	08-11-1993	ASTA Medica Aktiengesellschaft				
/SY/	4	EP 1 369 420 A1	12-10-2003	Aventis Pharma Deutschland GmbH		Г		
/SY/	5	WO 97/15300 A2	05-01-1997	ASTA Medica Aktiengesellschaft				
/SY/	6	WO 00/39118 A1	07-06-2000	Eli Lilly and Co.				
/SY/	7	WO 01/09612 A1	02-08-2001	Arzneimittelwerk Dresden GmbH				
/SY/	8	WO 01/22953 A2	04-05-2001	ASTA Medica AG				
/SY/	9	WO 01/92526 A1	12-06-2001	Bristol-Myers Squibb Co.		Г		
/SY/	10	WO 01/96540 A2	12-20-2001	Dupont Pharmaceuticals Co.				
/SY/	11	WO 02/18318 A1	03-07-2002	Wella Aktiengesellschaft		Г		
/SY/	12	WO 02/49628 A2	06-27-2002	Wyeth				

*EXAMINES: Initial if reference corridend, whether or not classin is in contempore with MEDE 600. Drue like through classics in it in closing with considered, include copy of this town when communication to applicate, "supplication survival contemporary and contemporary and in contemporary and in contemporary and in the contemporary and in

		NON PATENT LITERATURE DOCUMENTS
/SY/	13	American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 4ed., 1994, pp. 110-13, 393-444, and 623-27.
/SY/	14	BIALER et al., "Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI)," Epilepsy Res 2002, 51, 31-71.
/SY/	15	BLACKBURN-MUNRO et al., "The anticonvulsant retigabine attenuates nociceptive behaviours in rat models of persistent and neuropathic pain," Euro J Pharmacol 2003, 460, 109-16.
/SY/	16	CAPACIO et al., "Use of the accelerating rotarod for assessment of motor performance decrement induced by potential anticonvulsant compounds in nerve agent poisoning," Drug Chem Toxicol 1992, 15, 177-201.

Examiner	Date	
Signature	Considered	

Sheet

PTO/SB/08a/b (07-05)

PTUTSIVBBIO (U7-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449A/B/PTO

2

(Use as many sheets as necessary) of

3

Complete if Known					
Application Number	10/549,345				
Filing Date	September 14, 2005				
First Named Inventor	Daniel Rodriguez Greve				
Art Unit	Not Yet Assigned				
Examiner Name	Not Yet Assigned				
Attorney Docket Number	05432/100M668-US1				

Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, senial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/SY/		"Proposal for revised clinical and electroencephalographic classification of epileptic seizures," Epilepsia 1981, 22, 489-501.	
	18	Commission on Classification and Terminology of the International League Against Epilepsy, "Proposal for revised classification of epilepsies and epileptic syndromes," Epilepsia 1989, 30, 389-99.	
	19	COOPER et al., "Colocalization and coassembly of two human brain M-type potassium channel subunits that are mutated in epilepsy," Proceedings Nat Acad Sci USA 2000, 97, 4914-19.	
1.5	20	DAVOLL et al., "Folate antagonists. 2. 2.4-Diamino-6-[[aralky] and (heterocyclic)methyl]amino)quinazolines, a novel class of antimetabolites of interest in drug- resistant malaria and Chagas' disease," J Med Chem 1972, 15, 812-26.	
	21	EBERT et al., "Delayed sclerosis, neuroprotection, and limbic epileptogenesis after status epilepticus in the rat," Epilepsia 2002, 43 Suppl 5, 86-95.	
	22	GOLDSTEIN et al., "Localization of KCNQ and KCNE channel subunits in the central and peripheral nervous system of the rat," Soc Neuroscience Abstracts 2003, 53.8.	
	23	HAMILL et al., "Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches," Phlugers Arch 1981, 391, 85-100.	
	24	HARTZ et al., "The KCNQ channel opener retigabine has anxiolytic properties," J Psychopharmacol 2003, 17 Suppl 3, A28, B14.	
	25	JENTSCH, "Neuronal KCNQ potassium channels: physiology and role in disease," Nature Rev: Neuroscience 2000, 1, 21-30.	
	26	KEENEY et al., "Alterations in core body temperature, locomotor activity, and corticosterone following acute and repeated social defeat of male NMRI mice," Physiol Behavior 2001, 74, 177-84.	
	27	KIMBALL et al., "Biological effects of fast neutrons from an internal target cyclotron: physical methods and dominant lethals in <i>drosophila</i> ," Radiation Res 1957, 6, 173-87.	
	28	LITVINENKO et al., Dokl Chem 1981, 259, 317-320 (abstract).	
	29	MARRION, "Control of M-current," Annual Rev Phys 1997, 59, 483-504.	
	30	MEYER et al., "N²-(4-substituted-2,6-dicholorophenyl)-N¹,N¹-dimethylformamidines as antihypertensive and diuretic agents," J Med Chem 1984, 27, 1705-10.	
	31	NODA et al., "KCN channels in glial cells," Soc Neuroscience Abstracts 2003, 53.9.	
	32	NUTT et al., "Optimizing the pentetrazol infusion test for seizure threshold measurement," J Pharmacy Pharmacol 1986, 38, 697-98.	L
	33	PORRETTA et al., "Research on anti-bacterial and anti-fungal agents II. Synthesis and anti- fungal activity of new (1H-imidazol-1-ylmethyl)-benzenamine derivatives," Euro J Med Chem 1998, 23, 311-17.	
	34	RACINE, "Modification of seizure activity by electrical stimulation: II. Motor seizure," Electroencephalography Clin Neurophysiol 1972, 32, 281-94.	
	35	ROBBINS, "KCNQ potassium channels: physiology, pathophysiology, and pharmacology," Pharmcol Ther 2001, 90, 1-19.	
V	36	ROGAWSKI, "KCNQ2/KCNQ3 K* channels and the molecular pathogenesis of epilepsy: implications for therapy," Trends in Neuroscience 2000, 23, 393-98.	

Examiner	Date
Signature	Considered



Sheet

PTO/SB/08a/b (07-05) PTO/SSI0887b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

for form 1449A/B/PTO

3

(Use as many sheets as necessary) of

3

Complete if Known				
Application Number	10/549,345			
Filing Date September 14, 2005				
First Named Inventor	Daniel Rodriguez Greve			
Art Unit	Not Yet Assigned			
Examiner Name	Not Yet Assigned			
Attorney Docket Number	05432/100M668-US1			

Examiner Initials Cite Include name of the author (in CAPITAL EXTIFERS), tills of the atricle (when appropriate), title of the atricle (management of the author (in CAPITAL EXTIFERS)) Include name of the author (in CAPITAL EXTIFERS) Include name of the		T^2	
	38	SAGANICH et al., "Differential expression of genes encoding subthreshold-operating voltage- gated K ⁺ channels in brain," J Neuroscience 2001, 21, 4609-24.	
	39	SCALZO et al., "Studies on substrates with antibacterial and antifungal activity," Farmaco Edizone Scientifica 1986, 41, 292-307 (abstract).	
	40	SCHRODER et al., "KCNQ4 channel activation by BMS-204352 and retigabine," Neuropharmacol 2001, 40, 888-98.	
	41	SEYDEL et al., "Synthesis and quantitative structure-activity relationships of anticonvulsant 2,3,6-triaminopyridines," J Med Chem 1994, 37, 3016-22.	
	42	STARR et al., "Paradoxical facilitation of pilocarpine-induced seizures in the mouse by MK-801 and the nitric oxide synthesis inhibitor L-NAME," Pharmacol Blochem Behavior 1993, 45, 321- 25.	
	43	TANG et al., "Development and evaluation of high throughput functional assay methods for hERG potassium channel," J Biomol Screen 2001, 6, 325-31.	
	44	TATULIAN et al., "Activation of expressed KCNQ potassium currents and native neuronal M- type potassium currents by the anti-convulsant drug retigabine," J Neuroscience 2001, 21, 5535-45.	
	45	TOBER et al., D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures," Euro J Pharmacol 1996, 303, 163-69.	
	46	WATSON et al., "The novel anticonvulsant, gabapentin, protects against both convulsant and anxiogenic aspects of the ethanol withdrawal syndrome," Neuropharmacol 1997, 36, 1369-75.	
	47	WICKENDEN et al., "Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels," Molec Pharmacol 2000, 58, 591-600.	_
	48	WICKENDEN et al., "KCNQ channel expression in rat DRG following nerve ligation," Soc Neuroscience Abstracts 2002, 454.7.	
	49	WLAZ et al., "Frontal versus transcorneal stimulation to induce maximal electroshock seizures or kindling in mice and rats," Epilepsy Res 1998, 30, 219-29.	
V	50	YIN et al., "Palladium-catalyzed intermolecular coupling of aryl halides and amides," Organic Letters 2000, 2, 1101.	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	Examiner Signature	/Shawquia Young/	Date Considered	01/19/2009
--	-----------------------	------------------	--------------------	------------

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. in an envelope addressed to:

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

on March 28, 2006
Date

Signature

Signature

Typed or printed name of person signing Certificate

Registration Number: if applicable

Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Transmittal (1 page) Information Disclosure Statement (2 pages) Form PTO/SB/08 (3 pages) Copy of International Search Report (5 pages) Copies of 50 References (Document Nos. 1-50) Return Receipt Postcard